Table 4 Treatment-related adverse events
| Â | Grade, No. (%) | |||||||
|---|---|---|---|---|---|---|---|---|
nICT (n=26) | nCT (n=39) | |||||||
Any | 1 | 2 | ≥3 | Any | 1 | 2 | ≥3 | |
Treatment-related adverse events | 23 (88.5) | 17 (65.4) | 6 (23.1) | 0 (0.0) | 33 (84.6) | 27 (69.2) | 6 (15.4) | 0 (0.0) |
leukopenia | 21 (80.8) | 15 (57.7) | 6 (23.1) | 0 (0.0) | 25 (64.1) | 18 (46.2) | 7 (17.9) | 0 (0.0) |
Vomit | 10 (38.5) | 10 (38.5) | 0 (0.0) | 0 (0.0) | 15 (38.5) | 15 (38.5) | 0 (0.0) | 0 (0.0) |
Liver dysfunction | 5 (19.2) | 5 (19.2) | 0 (0.0) | 0 (0.0) | 8 (20.5) | 8 (20.5) | 0 (0.0) | 0 (0.0) |
Pruritus | 3 (11.5) | 2 (7.7) | 1 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
RCCEP | 1 (3.8) | 1 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Diarrhea | 2 (7.7) | 2 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Anemia | 7 (26.9) | 7 (26.9) | 0 (0.0) | 0 (0.0) | 13 (33.3) | 13 (33.3) | 0 (0.0) | 0 (0.0) |